Moderna/$MRNA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Ticker

$MRNA
Sector
Primary listing

Employees

5,800

Moderna Metrics

BasicAdvanced
$9.9B
-
-$7.53
1.83
-

What the Analysts think about Moderna

Analyst ratings (Buy, Hold, Sell) for Moderna stock.

Bulls say / Bears say

Q2 2025 revenue of $142 million surpassed Wall Street’s $112.9 million estimate, thanks to stronger-than-expected spring COVID booster sales and $800 million in cost cuts, narrowing adjusted loss to $2.13 per share versus the forecast $2.97 (Reuters)
The U.S. Court of Appeals for the Federal Circuit upheld a decision invalidating Alnylam’s patent claims targeting Moderna’s Spikevax in June 2025, strengthening Moderna’s intellectual property and lowering royalty risk (Reuters)
In August 2025, the UK Court of Appeal rejected Pfizer/BioNTech’s attempt to overturn Moderna’s COVID-19 vaccine patent victory, confirming the strength of Moderna’s core mRNA technology patent and reinforcing its global IP position (Reuters)
Moderna cut its 2025 revenue outlook to $1.5–$2.2 billion after deferring UK COVID-19 vaccine deliveries to 2026, causing shares to fall more than 4% despite beating Q2 sales estimates (Reuters)
The company withdrew its FDA application for a combination COVID-19 and flu vaccine in May 2025, pushing a potential launch to 2026 after regulators requested more trial data, highlighting regulatory and development challenges (Reuters)
U.S. HHS canceled over $700 million in funding for Moderna’s late-stage bird flu vaccine development in May 2025, casting doubt on its push to diversify beyond COVID-19 vaccines and raising concerns about pipeline support (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.

Moderna Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Moderna Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MRNA

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs